AbbVie, Inc. (ABBV)

AbbVie's stock has increased significantly, rising over 30% in the past six months, with a price of $227.99 as of October 24, 2025, up 20.22% over the past 12 months. The decline in Humira sales due to biosimilar competition has been offset by the performance of Skyrizi and Rinvoq. Acquisitions, such as ImmunoGen, have also impacted the stock. AbbVie reported its quarterly earnings on July 31st, missing EPS estimates but exceeding revenue expectations, with revenue up 6.6% year-over-year. Analyst price targets have been raised by several firms in recent months.

Specific demand seasonality for AbbVie's products is not explicitly detailed, but there are identified monthly seasonality patterns in ABBV's stock performance. Historically, the stock has shown predictable trends during certain months, with a trading strategy suggesting long positions in February, April, May, October, November, and December, and a short position in January. October, in particular, has historically favored a short bias for the stock.

AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing advanced therapies for complex and chronic diseases, operating within the Healthcare sector. Its business model centers on significant investment in R&D to create innovative pharmaceutical products, addressing various therapeutic areas, including immunology, oncology, neuroscience, aesthetics, and eye care. Major products include Humira, Skyrizi, and Rinvoq for immunology; Imbruvica and Venclexta for oncology; Vraylar, Ubrelvy, and Qulipta for neuroscience; Botox Cosmetic and Juvederm for aesthetics; and Mavyret for Hepatitis C, along with treatments for thyroid disease, Parkinson's disease, HIV, and complications of cystic fibrosis.

AbbVie offers its products globally through various channels, including physicians, wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers. The company maintains manufacturing facilities in the United States, Italy, Ireland, Costa Rica, Germany, France, and Singapore. Its headquarters are located in North Chicago, Illinois, U.S.A..

AbbVie's brand reputation has been influenced by its strategic navigation of the Humira patent cliff and its focus on innovation and pipeline expansion. The company has diversified its revenue streams with therapies like Skyrizi and Rinvoq and made acquisitions such as ImmunoGen. Ongoing R&D efforts, successful product launches, and strategic acquisitions contribute positively to its standing in the biopharmaceutical industry.

AbbVie Inc. is a publicly traded entity, with approximately 75% of its shares held by institutional investors. As of October 2025, AbbVie Inc. has 5,345 institutional owners and shareholders. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, and Capital Research Global Investors. Vanguard Group Inc. is the largest individual AbbVie shareholder, owning 10.04% of the company's shares. Retail investors also hold a significant portion, approximately 57.32% of the stock.